舒肝解郁胶囊治疗社交焦虑症疗效观察

Efficacy of Shugan Jieyu capsule on treating social anxiety disorder

目的评价舒肝解郁胶囊治疗社交焦虑症的疗效和安全性。方法选取66例社交焦虑症患者随机接受舒肝解郁胶囊(n=34)和帕罗西汀(n=32)治疗,以社交焦虑量表(LSAS)、临床疗效总评量表(CGI)及不良反应量表(TESS)评价疗效和不良反应。结果 LSAS评分分析显示,治疗后舒肝解郁胶囊治疗组与帕罗西汀治疗组LSAS评分均低于治疗前,且治疗2、4和6周与治疗前比较差异均具有统计学意义(P<0.05),但治疗前及治疗后各周组间比较差异均无统计学意义(P>0.05);舒肝解郁胶囊治疗组与帕罗西汀治疗组治疗前后CGI评分差异均无统计学意义(P>0.05);帕罗西汀治疗组有效率为70.58%,舒肝解郁胶囊治疗组有效率为68.75%,差异无统计学意义(P>0.05)。两组间治疗各周TESS评分比较差异也无统计学意义(P>0.05)。结论舒肝解郁胶囊治疗社交焦虑症疗效与帕罗西汀相当,且安全性良好。

Objective To observe the efficacy and safety of Shugan Jieyu capsule on treating social anxiety disorder. Methods A total of 66 cases of social anxiety disorder were randomly divided into Shugan Jieyu capsule group （n=34） and paroxetine group （n=32）. The efficacy and side effect were measured through LSAS, CGI and TESS. Results After treatment, LSAS scores were lower than before treatment in both Shugan Jieyu capsule and paroxetine groups, there were significant differences after 2, 4 and 6 weeks of treatment （P〈0.05）, but there was no significant difference between the two groups before and after treatment （P〉0.05）. There was no significant difference in CGI score between the two groups before and after treatment （P〉0.05）. The effective rate of two groups were 70.58% and 68.75% respectively and the difference was not statistically significant （P〉0.05）. Each week after treatment, there was no significant difference in TEES score between two groups （P〉0.05）. Conclusion Shugan Jieyu capsule shows equivalent clinical effects with paroxetine, and is safe.